Based on the evidence from multi-center long-term cardiovascular outcome trials (CVOTs) which showed that GLP-1 RAs could reduce cardiovascular mortality and the incidence of non-fatal myocardial infarction or non-fatal stroke, GLP-1 RAs have been incorporated into clinical guidelines by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [6–10]. Here, GLP1R is linked to stroke disorder.